SNBP News and Press, Sun BioPharma Inc From 08/21/20

Quick Take Sun BioPharma (SNBP) intends to raise $10 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is developing a treatment candidate for pancreatic cancer. SNBP is a thinly capitalized firm operating in a very difficu...

MINNEAPOLIS, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with pancreatic cancer, today provides a business update and reports financial results for the quarte...

MINNEAPOLIS, July 16, 2020 (GLOBE NEWSWIRE) --  Sun BioPharma, Inc. (OTCQB: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with pancreatic cancer, today announced the appointment of Jennifer K. Simpson, Ph.D., as Presi...

Quick Take Sun BioPharma (SNBP) has filed to raise $12 million in an IPO of its common stock, according to an S-1 registration statement. The firm is a clinical stage biopharma advancing a small molecule treatment candidate for pancreatic cancer and other solid tumors. SNBP is a tiny f...

Three IPOs raised $2.3 billion this past week, led by Dun & Bradstreet's (DNB) billion-dollar deal. All three IPOs upsized their deals and priced above the range. Commercial data analytics provider Dun & Bradstreet raised $1.7 billion at a $9 billion market cap. The long-standing com...

The FDA designates Sun BioPharma's ( OTCQB:SNBP ) lead candidate SBP-101 for Fast Track review for the treatment of patients with pancreatic ductal adenocarcinoma , the most common type of pancreatic cancer. More news on: Sun BioPharma, Inc., Healthcare stocks news, Read more ...

MINNEAPOLIS, June 30, 2020 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with pancreatic cancer, today announced receipt of Fast Track Designation from the U.S. Food and Drug...

MINNEAPOLIS, May 12, 2020 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with pancreatic cancer, today provides a business update and reports financial results for the quarter...

Acceleron Granted FDA Approval for Luspatercept Label Expansion Acceleron ( XLRN ) reported that the FDA has granted approval for the use of Reblozyl for treating anemia in certain adult patients with very low to intermediate risk myelodysplastic syndromes. These are the patients who did n...

MINNEAPOLIS, MN, April 03, 2020 (GLOBE NEWSWIRE) --  Sun BioPharma, Inc. (OTCQB: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced it will pause enrollment in its ongoing clinical trial of S...